EVP R&D, Chief Medical Officer
Thu, Feb 13, 2025
Feb 13
exercised or converted securities in ALKS
35,586 shares @ $24.59
Increased holdings by +21.30%
Net across this filing: -3.30% (-5,725 shares)
Option Exercise
Sale tied to a same-time option exercise